• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Thorax. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective

Giuseppe

Emeritus
[Source: Thorax, full text: (LINK). Abstract, edited.]

<CITE><ABBR>Thorax</ABBR> doi:10.1136/thoraxjnl-2013-203384 </CITE>
<CITE></CITE>
<CITE></CITE>Respiratory infection / Original article

Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective


Stefano Aliberti 1, Catia Cilloniz 2, James D Chalmers 3, Anna Maria Zanaboni 4, Roberto Cosentini 5, Paolo Tarsia 6, Alberto Pesci 1, Francesco Blasi 6, Antoni Torres 2

Author Affiliations: <SUP>1</SUP>Department of Health Science, University of Milan Bicocca, Clinica Pneumologica, AO San Gerardo, Monza, Italy <SUP>2</SUP>Hospital Cl?nic, IDIBAPS, Ciberes, Barcelona, Spain <SUP>3</SUP>Tayside Respiratory Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK <SUP>4</SUP>Computer Science Department, University of Milan, Milan, Italy <SUP>5</SUP>Emergency Medicine Department, IRCCS Fondazione Ca? Granda, Ospedale Maggiore Policlinico, Milan, Italy <SUP>6</SUP>Department of Pathophysiology and Transplantation, University of Milan, IRCCS Fondazione Ca? Granda Ospedale Maggiore Policlinico, Milan, Italy

Correspondence to Professor Francesco Blasi, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Fondazione Ca? Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, Milan I-20122, Italy; francesco.blasi@unimi.it

Received 6 February 2013 - Revised 9 April 2013 - Accepted 16 May 2013 - Published Online First 17 June 2013


Abstract

Background

Probabilistic scores have been recently suggested to identify pneumonia caused by multidrug-resistant (MDR) bacteria. The aim of the study was to validate both Aliberti and Shorr scores in predicting MDR pneumonia, comparing them with healthcare associated pneumonia (HCAP) classification.


Methods

Two independent European cohorts of consecutive patients hospitalised with pneumonia were prospectively evaluated in Barcelona, Spain (BC) and Edinburgh, UK (EC). Data on admission and during hospitalisation were collected. The predictive value of the three scores was explored for correctly indicating the presence of MDR pneumonia via a receiver-operating characteristic (ROC) curve.


Results

A total of 1591 patients in the BC and 1883 patients in the EC were enrolled. The prevalence of patients with MDR pathogen among those with isolated bacteria was 7.6% in the BC and 3.3% in the EC. The most common MDR pathogen found in both cohorts was MRSA, followed by MDR P aeruginosa. A significantly higher prevalence of MDR bacteria was found among patients in the intensive care unit (ICU). The two probabilistic scores, and particularly the Aliberti one, showed an area under the ROC curve higher than the HCAP classification in predicting MDR pneumonia, especially in the ICU.


Conclusions

Risk scores able to identify MDR pneumonia could help in developing strategies for antimicrobial stewardship.
-
-------
 
Back
Top Bottom